Presurgical neoadjuvant targeted molecular therapy for kidney cancer with concomitant vena cava tumor embolus: A clinical study

Guo,Gang; Cai,Wei; Li,Hongzhao; Gao,Jiangping; Ma,Xin; Dong,Jun; Fu,Weijun; Zhang,Xu

doi:10.3892/ol.2017.6131

Presurgical neoadjuvant targeted molecular therapy for kidney cancer with concomitant vena cava tumor embolus: A clinical study

Authors:
- Gang Guo
- Wei Cai
- Hongzhao Li
- Jiangping Gao
- Xin Ma
- Jun Dong
- Weijun Fu
- Xu Zhang
View Affiliations

Affiliations: Department of Urologic Surgery, The People's Liberation Army General Hospital, Beijing 100853, P.R. China
Published online on: May 5, 2017 https://doi.org/10.3892/ol.2017.6131
Pages: 369-375

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate presurgical neoadjuvant targeted therapy for patients with kidney cancer and vena cava tumor embolus, in order to examine its indications, therapeutic effects and optimal timing of surgery. Between June 2009 and June 2014, 12 patients from The People's Liberation Army General Hospital (Beijing, China) were diagnosed with kidney cancer with superior vena cava tumor embolus, and received presurgical neoadjuvant targeted therapy (sorafenib 400 mg twice a day or sunitinib 50 mg/day) for a median of 13.3 weeks. Patients included 8 males and 4 females, with a median age of 49.8 years. Kidney cancer was present on the left side in 3 patients and in the right side in 9 patients. The median tumor embolus length was 9.7 cm (range, 6.5‑14.0 cm). Tumor embolus levels II, III and IV, classified by the Mayo Clinic standard, were observed in 2, 6 and 4 patients, respectively. Median treatment time and average targeted therapy discontinuation time were observed to be longer in sunitinib‑treated patients compared with sorafenib‑treated patients. In total, 2 patients in the present study had partial remission (PR) and 8 patients had stable disease (SD); for tumor embolus, 4 patients had PR and 8 patients had SD. Tumor embolus length decreased by a median value of 18.7% (range, 0.0‑42.1%) or 1.8 cm (range, 0.1‑5.2 cm). Tumor diameter decreased by a median value of 8.6% (range, 0.0‑38.9%) or 0.7 cm (range, 0.0‑3.5 cm). The level of the tumor thrombus, classified by the Mayo Clinic standard, was observed to decrease following sunitinib treatment, including two cases downgraded from tumor thrombus level IV to II, one case from level IV to III and two cases from level III to II. Presurgical neoadjuvant targeted molecular therapy may have the potential to reduce the tumor stage of patients, as well as decreasing the surgical difficulty for radical nephrectomy.

View Figures

View References

1	Bhatt JR and Finelli A: Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol. 11:517–525. 2014. View Article : Google Scholar : PubMed/NCBI
2	González J, Gorin MA and Ciancio G: Long-term survival after radical surgery for renal cell carcinoma with tumour thrombus. BJU Int. 111:E8–E9. 2013. View Article : Google Scholar : PubMed/NCBI
3	Novick AC and Campbell SC: Renal TumorsCampbell's Urology. Walsh PC, Retik AB, Vaughan ED and Wein AJ: WB Saunders; Philadephia: pp. 2672–2731. 2002
4	Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ and Belldegrun AS: Neoadjuvant targeted therapy and advanced kidney cancer: Observations and implications for a new treatment paradigm. BJU Int. 102:692–696. 2008. View Article : Google Scholar : PubMed/NCBI
5	Di Silverio F, Sciarra A, Parente U, Andrea A, Von Heland M, Panebianco V and Passariello R: Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int. 80:451–453. 2008. View Article : Google Scholar : PubMed/NCBI
6	Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ and Perrotte P: Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol. 53:845–848. 2008. View Article : Google Scholar : PubMed/NCBI
7	Peters I, Winkler M, Jüttner B, Teebken OE, Herrmann TR, von Klot C, Kramer M, Reichelt A, Abbas M, Kuczyk MA and Merseburger AS: Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: A case report. World J Urol. 32:245–248. 2014. View Article : Google Scholar : PubMed/NCBI
8	Horn T, Thalgott MK, Maurer T, Hauner K, Schulz S, Fingerle A, Retz M, Gschwend JE and Kübler HR: Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus. Anticancer Res. 32:1729–1735. 2012.PubMed/NCBI
9	Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA and Rathmell WK: Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology. 72:864–868. 2008. View Article : Google Scholar : PubMed/NCBI
10	Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Nishikawa T, Nakano M and Tanabe K: Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: Clinical results and histopathological therapeutic effects. Jpn J Clin Oncol. 40:1173–1179. 2010. View Article : Google Scholar : PubMed/NCBI
11	Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, et al: Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 28:1502–1507. 2010. View Article : Google Scholar : PubMed/NCBI
12	Rini BI, Garcia J, Elson P, Wood L, Shah S, Stephenson A, Salem M, Gong M, Fergany A, Rabets J, et al: The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol. 187:1548–1554. 2012. View Article : Google Scholar : PubMed/NCBI
13	Cost NG, Delacroix SE Jr, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, et al: The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 59:912–918. 2011. View Article : Google Scholar : PubMed/NCBI
14	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
15	National Cancer Institute, . Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov
16	Kiernan JA: Histological and Histochemical Methods: Theory and Practice. 4th. Scion; Bloxham, UK: 2008
17	Bex A, Kroon BK and de Bruijn R: Is there a role for neoadjuvant targeted therapy to downsize primary tumors for organ sparing strategies in renal cell carcinoma? Int J Surg Oncol. 2012:2504792012.PubMed/NCBI
18	Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T and Bex A: Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. Urology. 81:111–115. 2013. View Article : Google Scholar : PubMed/NCBI
19	Vogelzang NJ, Samlowski W and Weissman A: Long-term response in primary renal cancer to sequential antiangiogenic therapy. J Clin Oncol. 27:e106–e107. 2009. View Article : Google Scholar : PubMed/NCBI
20	Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B and Sternberg CN: Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 77:48–62. 2011. View Article : Google Scholar : PubMed/NCBI
21	Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, Mulders P and Kataja V; ESMO Guidelines Working Group, : Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23 Suppl 7:vii65–vii71. 2012. View Article : Google Scholar : PubMed/NCBI
22	Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, et al: Bevacizumab plus interferon alfa2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet. 370:2103–2111. 2007. View Article : Google Scholar : PubMed/NCBI
23	Escudier R, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
24	Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, et al: Pazopanib in locally advanced or metastatis renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
25	Thomas AA, Rini BI, Stephenson AJ, Garcia JA, Fergany A, Krishnamurthi V, Novick AC, Gill IS, Klein EA, Zhou M, et al: Surgical resection of renal cell carcinoma after targeted therapy. J Urol. 182:881–886. 2009. View Article : Google Scholar : PubMed/NCBI
26	Chapin BF, Delacroix SE Jr, Culp SH, Gonzalez GM Nogueras, Tannir NM, Jonasch E, Tamboli P and Wood CG: Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 60:964–971. 2011. View Article : Google Scholar : PubMed/NCBI